LSD1 inhibitors: a patent review (2010-2015)

References

• Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004 Dec 29;119(7):941–953.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang Y, Wang F, et al. Crystal structure of human histone lysine-specific demethylase 1 (LSD1). Proc Natl Acad Sci U S A 2006 Sep 19;103(38):13956–13961.
   PubMed Web of Science ®Google Scholar
• Walport LJ, Hopkinson RJ, Schofield CJ. Mechanisms of human histone and nucleic acid demethylases. Curr Opin Chem Biol. 2012 Dec;16(5–6):525–534.
   PubMed Web of Science ®Google Scholar
• Forneris F, Binda C, Dall’Aglio A, et al. A highly specific mechanism of histone H3-K4 recognition by histone demethylase LSD1. J Biol Chem. 2006 Nov 17;281(46):35289–35295.
   PubMed Web of Science ®Google Scholar
• Forneris F, Binda C, Vanoni MA, et al. Human histone demethylase LSD1 reads the histone code. J Biol Chem. 2005 Dec 16;280(50):41360–41365.
   PubMed Web of Science ®Google Scholar
• Lee MG, Wynder C, Cooch N, et al. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature. 2005 Sep 15;437(7057):432–435.
   PubMed Web of Science ®Google Scholar
• Shi YJ, Matson C, Lan F, et al. Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell. 2005 Sep 16;19(6):857–864.
   PubMed Web of Science ®Google Scholar
• Chau CM, Deng Z, Kang H, et al. Cell cycle association of the retinoblastoma protein Rb and the histone demethylase LSD1 with the Epstein-Barr virus latency promoter Cp. J Virol. 2008 Apr;82(7):3428–3437.
   PubMed Web of Science ®Google Scholar
• Huang J, Sengupta R, Espejo AB, et al. p53 is regulated by the lysine demethylase LSD1. Nature. 2007 Sep 6;449(7158):105–108.
   PubMed Web of Science ®Google Scholar
• Wang J, Hevi S, Kurash JK, et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat Genet. 2009 Jan;41(1):125–129.
   PubMed Web of Science ®Google Scholar
• Yuan B, Zhang J, Wang H, et al. 6-Thioguanine reactivates epigenetically silenced genes in acute lymphoblastic leukemia cells by facilitating proteasome-mediated degradation of DNMT1. Cancer Res. 2011 Mar 1;71(5):1904–1911.
   PubMed Web of Science ®Google Scholar
• Cho HS, Suzuki T, Dohmae N, et al. Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer Res. 2011 Feb 1;71(3):655–660.
   PubMed Web of Science ®Google Scholar
• Yang Z, Jiang J, Stewart DM, et al. AOF1 is a histone H3K4 demethylase possessing demethylase activity-independent repression function. Cell Res. 2010 Mar;20(3):276–287.
   PubMed Web of Science ®Google Scholar
• Lim S, Janzer A, Becker A, et al. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis. 2010 Mar;31(3):512–520.
   PubMed Web of Science ®Google Scholar
• Scoumanne A, Chen X. The lysine-specific demethylase 1 is required for cell proliferation in both p53-dependent and -independent manners. J Biol Chem. 2007 May 25;282(21):15471–15475.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang H, Chen Y, et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell. 2009 Aug 21;138(4):660–672.
   PubMed Web of Science ®Google Scholar
• Metzger E, Wissmann M, Yin N, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005 Sep 15;437(7057):436–439.
   PubMed Web of Science ®Google Scholar
• Wissmann M, Yin N, Muller JM, et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol. 2007 Mar;9(3):347–353.
   PubMed Web of Science ®Google Scholar
• Schulte JH, Lim S, Schramm A, et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res. 2009 Mar 1;69(5):2065–2071.
   PubMed Web of Science ®Google Scholar
• Yokoyama A, Takezawa S, Schule R, et al. Transrepressive function of TLX requires the histone demethylase LSD1. Mol Cell Biol. 2008 Jun;28(12):3995–4003.
   PubMed Web of Science ®Google Scholar
• Hayami S, Kelly JD, Cho HS, et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer. 2011 Feb 1;128(3):574–586.
   PubMed Web of Science ®Google Scholar
• Huang Y, Stewart TM, Wu Y, et al. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res. 2009 Dec 1;15(23):7217–7228.
   PubMed Web of Science ®Google Scholar
• Harris WJ, Huang X, Lynch JT, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell. 2012 Apr 17;21(4):473–487.
   PubMed Web of Science ®Google Scholar
• Murray-Stewart T, Woster PM, Casero RA Jr. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines. Amino Acids. 2014 Mar;46(3):585–594.
   PubMed Web of Science ®Google Scholar
• Fiskus W, Sharma S, Shah B, et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia. 2014 Nov;28(11):2155–2164.
   PubMed Web of Science ®Google Scholar
• Schenk T, Chen WC, Gollner S, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med. 2012;18(4):605–611.
   PubMed Web of Science ®Google Scholar
• Prusevich P, Kalin JH, Ming SA, et al. A selective phenelzine analogue inhibitor of histone demethylase LSD1. ACS Chem Biol. 2014 Jun 20;9(6):1284–1293.
   PubMed Web of Science ®Google Scholar
• Huang Y, Vasilatos SN, Boric L, et al. Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells. Breast Cancer Res Treat. 2012 Feb;131(3):777–789.
   PubMed Web of Science ®Google Scholar
• Yu SE, Jang YK. The histone demethylase LSD1 is required for estrogen-dependent S100A7 gene expression in human breast cancer cells. Biochem Biophys Res Commun. 2012 Oct 19;427(2):336–342.
   PubMed Web of Science ®Google Scholar
• Foster CT, Dovey OM, Lezina L, et al. Lysine-specific demethylase 1 regulates the embryonic transcriptome and CoREST stability. Mol Cell Biol. 2010 Oct;30(20):4851–4863.
   PubMed Web of Science ®Google Scholar
• Whyte WA, Bilodeau S, Orlando DA, et al. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Nature. 2012 Feb 9;482(7384):221–225.
   PubMed Web of Science ®Google Scholar
• Kerenyi MA, Shao Z, Hsu YJ, et al. Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. Elife. 2013;2:e00633.
   PubMed Web of Science ®Google Scholar
• Zhu D, Holz S, Metzger E, et al. Lysine-specific demethylase 1 regulates differentiation onset and migration of trophoblast stem cells. Nat Commun. 2014;5:3174.
   PubMed Web of Science ®Google Scholar
• Sakane N, Kwon HS, Pagans S, et al. Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1). PLoS Pathog. 2011 Aug;7(8):e1002184.
   PubMed Web of Science ®Google Scholar
• Liang Y, Vogel JL, Narayanan A, et al. Inhibition of the histone demethylase LSD1 blocks alpha-herpesvirus lytic replication and reactivation from latency. Nat Med. 2009 Nov;15(11):1312–1317.
   PubMed Web of Science ®Google Scholar
• Gu H, Roizman B. Engagement of the lysine-specific demethylase/HDAC1/CoREST/REST complex by herpes simplex virus 1. J Virol. 2009 May;83(9):4376–4385.
   PubMed Web of Science ®Google Scholar
• Zhou G, Du T, Roizman B. The role of the CoREST/REST repressor complex in herpes simplex virus 1 productive infection and in latency. Viruses. 2013 May;5(5):1208–1218.
   PubMed Web of Science ®Google Scholar
• Du T, Zhou G, Khan S, et al. Disruption of HDAC/CoREST/REST repressor by dnREST reduces genome silencing and increases virulence of herpes simplex virus. Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15904–15909.
   PubMed Web of Science ®Google Scholar
• Zhou G, Te D, Roizman B. The CoREST/REST repressor is both necessary and inimical for expression of herpes simplex virus genes. MBio. 2011;2(1):e00313–10.
   Web of Science ®Google Scholar
• Musri MM, Carmona MC, Hanzu FA, et al. Histone demethylase LSD1 regulates adipogenesis. J Biol Chem. 2010 Sep 24;285(39):30034–30041.
   PubMed Web of Science ®Google Scholar
• Janzer A, Lim S, Fronhoffs F, et al. Lysine-specific demethylase 1 (LSD1) and histone deacetylase 1 (HDAC1) synergistically repress proinflammatory cytokines and classical complement pathway components. Biochem Biophys Res Commun. 2012 May 18;421(4):665–670.
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011 May 19;473(7347):317–325.
   PubMed Web of Science ®Google Scholar
• Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J. 2015 Feb 21;36(8):482–9c.
   PubMed Web of Science ®Google Scholar
• Reddy MA, Villeneuve LM, Wang M, et al. Role of the lysine-specific demethylase 1 in the proinflammatory phenotype of vascular smooth muscle cells of diabetic mice. Circ Res. 2008 Sep 12;103(6):615–623.
   PubMed Web of Science ®Google Scholar
• Zheng YC, Ma J, Wang Z, et al. A systematic review of histone lysine-specific demethylase 1 and its inhibitors. Med Res Rev. 2015;35(5):1032–1071.
   PubMed Web of Science ®Google Scholar
• Mohammad Helai P, Smitheman Kimberly N, Kamat Chandrashekhar D, et al. A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell. 2015;28(1):57–69.
   PubMed Web of Science ®Google Scholar
• Kutz CJ, Holshouser SL, Marrow EA, et al. 3,5-Diamino-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitors. Medchemcomm. 2014 Dec;5(12):1863–1870.
   PubMed Web of Science ®Google Scholar
• Castro J. inventor Oryzon Genomics S.A., Spain. assignee. Preparation of N-(2-phenylcyclopropyl) amino acid derivatives for treatment of cancer patent EP2177502A1. 2010.
   Google Scholar
• Guibourt N, Ortega Munoz A, Castro-Palomino Laria J. inventors; Oryzon Genomics, S.A., Spain. assignee. Preparation of N-(2-phenylcyclopropyl) amino acid oxidase inhibitory derivatives for treatment of cancer patent WO2010043721A1. 2010.
   Google Scholar
• Zirkle CL, Kaiser C, Tedeschi DH, et al. 2-substituted cyclopropylamines. II. Effect of structure upon monoamine oxidase-inhibitory activity as measured in vivo by potentiation of tryptamine convulsions. J Med Pharm Chem. 1962;5(6):1265–1284.
   Google Scholar
• Ortega Munoz A, Castro-Palomino Laria J, Fyfe MCT. inventors; Oryzon Genomics S. A., Spain. assignee. Lysine specific demethylase-1 inhibitors and their use patent WO2011035941A1. 2011.
   Google Scholar
• Castro-Palomino Laria J, Ortega Munoz A, Guibourt N, et al. inventors; Oryzon Genomics, S.A., Spain. assignee. Potent selective LSD1 inhibitors or LSD1/MAO-B dual inhibitors for antiviral use patent WO2011106105A2. 2011.
   Google Scholar
• Baker JA, Fyfe MCT. inventors; Oryzon Genomics, S.A., Spain. assignee. Lysine specific demethylase-1 (LSD1) inhibitors for diseases and disorders associated with hepadnaviridae patent WO2011106106A2. 2011.
   Google Scholar
• Baker JA, Fyfe MCT. inventors; Oryzon Genomics, S.A., Spain. assignee. Lysine specific demethylase-1 (LSD1) inhibitors for diseases and disorders associated with hepadnaviridae patent WO2011106573A2. 2011.
   Google Scholar
• Ortega Munoz A, Castro-Palomino Laria J, Fyfe MCT. inventors; Oryzon Genomics S.A., Spain. assignee. Preparation of heteroaryl cyclopropylamines as selective lysine specific demethylase-1 inhibitors, for treating cancer and viral infections patent WO2011131697A1. 2011.
   Google Scholar
• Castro-Palomino Laria J, Fyfe MCT, Martinell Pedemonte M, et al. inventors; Oryzon Genomics S.A., Spain. assignee. Preparation of cyclopropylamine compounds as inhibitors of oxidases patent WO2012045883A1. 2012.
   Google Scholar
• Fyfe MCT, Ortega AM, Laria JC-P. et al. inventors; Oryzon Genomics S.A., Spain. assignee. Preparation of cyclopropylamine derivatives as LSD1 inhibitors patent WO2012013727A1. 2012.
   Google Scholar
• Ortega Munoz A, Fyfe Matthew CT, Martinell Pedemonte M. et al. inventors; Oryzon Genomics S.A., Spain. assignee. Preparation of arylcyclopropylamine derivatives as LSD1 inhibitors patent WO2012013728A1. 2012.
   Google Scholar
• Maes T, Buesa Arjol C. inventors; Oryzon Genomics S.A., Spain. assignee. Selective lysine specific demethylase-1 (LSD1) and dual LSD1/monoamine oxidase B (MAO-B) inhibitors for modulating diseases associated with alterations in protein conformation patent WO2012042042A1. 2012.
   Google Scholar
• Baker JA, Fyfe MCT. inventors; Oryzon Genomics, S. A., Spain. assignee. Lysine demethylase (LSD) inhibitors for treatment and prevention of diseases associated with Flaviviridae infection patent WO2012072713A2. 2012.
   Google Scholar
• Baker JA, Castro Palomino J, Fyfe MCT. et al. inventors; Oryzon Genomics S.A., Spain. assignee. Lysine demethylase inhibitors for treatment of myeloproliferative disorders patent WO2012107498A1. 2012.
   Google Scholar
• Fyfe MCT, Maes T, Martinell Pedemonte M. et al. inventors; Oryzon Genomics S.A., Spain. assignee. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders patent WO2012107499A1. 2012.
   Google Scholar
• Maes T, Martinell Pedemonte M. inventors; Oryzon Genomics, S.A., Spain. assignee. Lysine demethylase inhibitors for thrombosis and cardiovascular diseases patent WO2012156537A2. 2012.
   Google Scholar
• Maes T, Martinell Pedemonte M, Castro-Palomino Laria JC. inventors; Oryzon Genomics, S. A., Spain. assignee. Lysine demethylase inhibitors for inflammatory diseases or conditions patent WO2012156531A2. 2012.
   Google Scholar
• Ortega Munoz A, Fyfe MCT, Martinell Pedemonte M, et al. inventors; Oryzon Genomics, S.A., Spain. assignee. Aryl- and heteroarylcyclopropylamine compounds as LSD1 inhibitors and their preparation patent WO2013057320A1. 2013.
   Google Scholar
• Ortega Munoz A, Fyfe MCT, Martinell Pedemonte M, et al. inventors; Oryzon Genomics, S.A., Spain. assignee. Aryl- and heteroarylcyclopropylamine compounds as LSD1 inhibitors and their preparation patent WO2013057322A1. 2013.
   Google Scholar
• Dg M, Pollock J. inventors; Duke University, USA. assignee. trans-2-Arylcyclopropylamine derivatives as inhibitors of lysine-specific demethylase 1, monoamine oxidase A and B, and their preparation and use for the treatment of cancer patent US20100324147A1. 2010.
   Google Scholar
• McCafferty DG, Hwang S, Pollock JA, et al. inventors; Duke University, USA. assignee. Preparation of arylcyclopropylamine compounds useful for the treatment of breast cancer patent US20140343118A1. 2014.
   Google Scholar
• Minucci S, Mai A, Mattevi A. inventors; Universita degli Studi di Roma “La Sapienza”, Italy; Fondazione IEO; Universita degli Studi di Pavia; Universita degli Studi di Milano. assignee. Preparation of tranylcypromine derivatives as inhibitors of histone demethylase patent WO2011131576A1. 2011.
   Google Scholar
• Vianello P, Varasi M, Mercurio C, et al. Composés de cyclopropylamine à utiliser en tant qu’inhibiteurs de l’histone déméthylase. Google Patents 2015.
   Google Scholar
• Minucci S, Monestiroli S, Giavara S, et al. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood. 2002 Oct 15;100(8):2989–2995.
   PubMed Web of Science ®Google Scholar
• Johnson NW, Kasparec J, Miller WH, et al. inventors; GlaxoSmithKline LLC, USA. assignee. Preparation of cyclopropylamines as LSD1 inhibitors in the treatment of cancer patent WO2012135113A2. 2012.
   Google Scholar
• Suzuki T, Itoh Y, Ogasawara D, et al. inventors; Kyoto Prefectural Public University Corporation, Japan; Public University Corporation Nagoya City University; Educational Corporation Kansai Bunri Sougougakuen; Frontier Pharma Inc.; Kyoto University. assignee. N6-Cyclopropyllydine derivatives as LSD1-selective inhibitors, and their pharmaceutical uses patent WO2014084298A1. 2014.
   Google Scholar
• McCall J, Rienhoff H, Clare M. inventors; Imago BioSciences, USA. assignee. Preparation of benzamides as KDM1A inhibitors for the treatment of disease patent WO2014164867A1. 2014.
   Google Scholar
• Zhang H. inventor University of Nevada, USA. assignee. Novel suicidal LSD1 inhibitors targeting SOX2-expressing cancer cells patent WO2014194280A2. 2014.
   Google Scholar
• Wu L, Courter JR, He C, et al. inventors; Incyte Corporation, USA. assignee. Cyclopropylamines as LSD1 inhibitors and their preparation patent US20150225394A1. 2015.
   Google Scholar
• Wu L, Courter JR, He C, et al. inventors; Incyte Corporation, USA. assignee. Cyclopropylamines as LSD1 inhibitors and their preparation patent US20150225379A1. 2015.
   Google Scholar
• Wu L, Courter JR, He C, et al. inventors; Incyte Corporation, USA. assignee. Cyclopropylamines as LSD1 inhibitors and their preparation patent US20150225401A1. 2015.
   Google Scholar
• Wu L, He C, Qian D-Q, et al. inventors; Incyte Corporation, USA. assignee. Cyclopropylamines as LSD1 inhibitors and their preparation patent US20150225375A1. 2015.
   Google Scholar
• Mackowiak M, Bator E, Latusz J, et al. Prenatal MAM administration affects histone H3 methylation in postnatal life in the rat medial prefrontal cortex. Eur Neuropsychopharmacol. 2014 Feb;24(2):271–289.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011 Apr;10(4):309–319.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Hattori Y, Toyofuku M, et al. Cyclopropanamine compound and use thereof. Google Patents 2015.
   Google Scholar
• Wang Y, Murray-Stewart T, Devereux W, et al. Properties of purified recombinant human polyamine oxidase, PAOh1/SMO. Biochem Biophys Res Commun. 2003 May 16;304(4):605–611.
   PubMed Web of Science ®Google Scholar
• Bi X, Lopez C, Bacchi CJ, et al. Novel alkylpolyaminoguanidines and alkylpolyaminobiguanides with potent antitrypanosomal activity. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3229–3232.
   PubMed Web of Science ®Google Scholar
• Casero RA, Woster PM. inventors; The Johns Hopkins University, USA. assignee. Preparation of (bis)urea and (bis)thiourea derivatives as epigenic modulators of lysine-specific demethylase 1 patent WO2011022489A2. 2011.
   Google Scholar
• Ra C, Bytheway I, Pm W. inventors; The Johns Hopkins University, USA. assignee. Benzenamine derivatives as epigenetic modulators of lysine-specific demethylase 1 and their preparation and use for the treatment of LSD1-associated diseases patent WO2012034116A2. 2012.
   Google Scholar
• Zhang H, Ye T, Quan J, et al. inventors; Nevada Cancer Institute, USA; Shenzhen Graduate School of Peking University. assignee. Histone demethylase inhibitors and uses thereof for treatment of cancer patent WO2012071469A2. 2012.
   Google Scholar
• Chen YK, Kanouni T, Kaldor SW, et al. inventors; Quanticel Pharmaceuticals, Inc., USA. assignee. Preparation of pyrimidine derivatives as inhibitors of lysine specific demethylase-1 patent WO2015089192A1. 2015.
   Google Scholar
• Vankayalapati H, Sharma S, Sorna V. inventors; University of Utah, USA. assignee. Preparation of substituted benzimidazoles as lysine-specific demethylase 1 (LSD1) inhibitors patent WO2015031564A2. 2015.
   Google Scholar
• Vankayalapati H, Sorna V, Warner SL, et al. inventors; University of Utah Research Foundation, USA. assignee. Substituted (E)-N’-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors patent WO2013025805A1. 2013.
   Google Scholar
• Vankayalapati H, Sorna V, Warner SL, et al. inventors; University of Utah Research Foundation, USA. assignee. Preparation of substituted (E)-N’-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors patent WO2014205213A1. 2014.
   Google Scholar
• Vankayalapati H, Sorna V, Warner SL, et al. inventors; University of Utah, USA. assignee. Preparation of substituted (E)-N’-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors patent US20140163017A1. 2014.
   Google Scholar
• Woster PM, Kutz CJ. inventors; MUSC Foundation for Research Development, USA. assignee. Aminotriazole- and aminotetrazole-based KDM1A inhibitors as epigenetic modulators patent WO2015120281A1. 2015.
   Google Scholar
• Cole P, Ming S, Prusevich P, et al. inventors; The Johns Hopkins University, USA; Intonation Research Laboratories. assignee. Phenelzine analogs as inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylases (HDACs) and their preparation patent WO2015134973A1. 2015.
   Google Scholar
• Culhane JC, Szewczuk LM, Liu X, et al. A mechanism-based inactivator for histone demethylase LSD1. J Am Chem Soc. 2006 Apr 12;128(14):4536–4537.
   PubMed Web of Science ®Google Scholar
• Szewczuk LM, Culhane JC, Yang M, et al. Mechanistic analysis of a suicide inactivator of histone demethylase LSD1. Biochemistry. 2007 Jun 12;46(23):6892–6902.
   PubMed Web of Science ®Google Scholar
• Woster PM, Kumarasinghe IR. inventors; MUSC Foundation for Research Development, USA. assignee. Cyclic peptide inhibitors of lysine-specific demethylase 1 patent US20150065434A1. 2015.
   Google Scholar
• Rao S, Zafar A. inventors; University of Canberra, Australia. assignee. Methods and compositions comprising lysine-specific demethylase inhibitors (LSD) for inhibiting growth of cancer stem cells patent WO2014205511A1. 2014.
   Google Scholar
• Shi YG, Lian CG. inventors; The Brigham and Women’s Hospital, Inc., USA. assignee. Treatment of cancer by inhibiting histone lysine specific demethylase 1 and 2 patent WO2013033688A1. 2013.
   Google Scholar
• Vilaplana-Perez C, Aunon D, Garcia-Flores LA, et al. Hydroxytyrosol and potential uses in cardiovascular diseases, cancer, and AIDS. Front Nutr. 2014;1:18.
   PubMedGoogle Scholar
• McCord DE, Karagiannis T. inventors; USA. assignee. Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD1 inhibition patent WO2014085613A1. 2014.
   Google Scholar
• Lee MG, Wynder C, Bochar DA, et al. Functional interplay between histone demethylase and deacetylase enzymes. Mol Cell Biol. 2006 Sep;26(17):6395–6402.
   PubMed Web of Science ®Google Scholar
• Forneris F, Battaglioli E, Mattevi A, et al. New roles of flavoproteins in molecular cell biology: histone demethylase LSD1 and chromatin. Febs J. 2009 Aug;276(16):4304–4312.
   PubMed Web of Science ®Google Scholar